We Be Now
The companion app patients use during their ketamine sessions.
Built by a biomedical engineer (M.Eng, Cornell) with 100+ personal Spravato sessions.
See how clinics are filling the 2-hour silence.
Built by a patient. Designed for the clinic.
Katie Dickieson
Founder, We Be Now
- M.Eng Biomedical Engineering, Cornell University
- Two-year Spravato + IV ketamine patient (100+ personal sessions)
- Designed and built We Be Now solo over 6 months
“I spent 100+ sessions in your chairs asking: if my brain is at peak neuroplasticity, why is the app empty? Every feature is validated against my own clinical data.”
The 2-hour window is yours to own.
Peak neuroplasticity. A federally mandated 2-hour observation window where the brain is rewiring in real time, and what it encodes, persists.
You own it. Most clinics offer nothing. That gap is your competitive advantage, if you fill it before the clinic next door does.
The science. The strategy.
A single sub-anesthetic dose of ketamine activates the mTOR pathway and triggers new dendritic spine synapse formation in the prefrontal cortex within 2 hours: a discrete neuroplastic window driving the antidepressant response.
Li N, Lee B, Liu RJ, et al. Science 2010;329(5994):959-964
We Be Now is built around this exact window, turning a neurochemical event into a directed plasticity event.
Spravato is available only through a restricted FDA REMS program. You control the 2-hour neuroplastic window completely. Every patient must be observed by a healthcare provider in a certified setting for at least 2 hours after each dose.
SPRAVATO (esketamine) US Prescribing Information, Janssen / FDA REMS, 2025 label
Your control of this window is an advantage no competitor can copy. No telehealth service can reach a patient sitting in your office. We Be Now is how you make it count.
In the pivotal TRANSFORM-2 trial, intranasal esketamine plus a newly initiated oral antidepressant produced ~50% remission and ~70% response rates in treatment-resistant depression.
Popova V, Daly EJ, Trivedi M, et al. Am J Psychiatry 2019;176(6):428-438
We Be Now is a durability and integration layer on top of these numbers, protecting the remission clinics already achieve.
Adjunctive psychotherapy and intentional ‘set and setting’ during and after dosing significantly enhance and prolong antidepressant response, leveraging the post-dose plasticity window.
Joneborg I, Lee Y, Di Vincenzo JD, et al. Frontiers in Psychiatry 2021;12:710338
The clinical rationale for We Be Now: a scalable integration protocol without requiring a therapist in the room.
What it does.
Different by design.
600+ clinics · VC-backed clinical SaaS
- Clinical-beige, neuroscience-forward medical UX
- Patient data locked inside the clinic’s portal, doesn’t travel with the patient
- 5 to 15 min mindfulness microdoses or generic ambient music
- Built around the clinic workflow. The patient is a data point
Integrates with your workflow · patient-owned data feeds your outcomes
- Results-forward, not clinical-beige. Speaks the patient’s language
- Patient-owned journal stays private to the patient. You see de-identified engagement, which is why they write honestly
- 60-minute Solfeggio + voice-subliminal soundscapes tuned to a full Spravato window
- EFT + chakra + subliminal-affirmation library, the wellness-engaged patient already wants this
- Founded by a current ketamine patient with M.Eng Cornell, not a VC-funded PM
Limitless owns the clinical patient. We own the wellness-engaged one, and you own the outcomes data either way.
44 tracks. Timed to the dose.
+ 28 more across meditations, hypnoses, breathing, soundscapes, EFT & chakra journeys
Each customizable to your dosing protocol (Spravato 56mg / 84mg, IV ketamine). Patients begin the session-specific track automatically upon check-in.
The market is growing up.
Spravato passed $1B
Johnson & Johnson's Spravato crossed $1 billion in 2024 sales, up more than 55 percent year over year, and reached blockbuster status. Insurers and clinics are following.
500 to 750 clinics
Ketamine and Spravato clinics now number in the hundreds nationwide, in a US market estimated near $5 billion and growing about 10 percent a year. We have already mapped nearly 500.
One part is unserved
The dosing chair is well covered. The two hours after, and the days between sessions, are where almost no one has built. That is the window We Be Now is made for.
Sources: J&J FY2024 results and US ketamine-clinic market research, 2025.
What you get.
🎯Patient retention
App-based engagement tools are linked to meaningfully higher completion (Linardon 2019 meta-analysis). Engaged patients finish what they start.
📈Between-session data
Structured mood and insight tracking after every session, so you can see engagement and follow-up in real time. We commit to pilot data within 30 days.
✨Clinic differentiation
Most clinics offer nothing during the federally mandated 2-hour observation window. Patients notice. So do referring providers.
🛠️Zero new staff burden
Patients self-serve through the app. No new hire, no new workflow. Additive to your existing observation, never a replacement.
🛡️REMS-compliant by design
The 2-hour observation requirement is preserved exactly as the prescribing information requires. We Be Now works inside your existing clinical structure.
🔒HIPAA compliance in progress
Full HIPAA compliance is expected next quarter. We Be Now is a wellness companion, so your clinical records stay in your own systems either way.
Most clinics earn back the license cost within the first few retained patients.
How a clinic pilot works.
Sign a one-page Evaluation Agreement (NDA + eval license).
We Be Now installs on patient phones from the App Store, live today at apps.apple.com/app/we-be-now-companion.
90-day founding pilot: patients use during sessions, you gather feedback.
Decide on a per-seat or annual license; we sign an MSA together.
You retain full control. We retain IP. Zero data sharing outside your clinic until you sign the MSA.
Your risk is zero.
$0 upfront during the 90-day founding pilot. No license fee. No setup cost. No new hire.
If you’re not seeing engagement lift by day 30, we stop. No questions, no clawback.
Your data stays with you. REMS-compliant by design. HIPAA compliance is in progress, expected next quarter.
Additive to your existing observation workflow. Never a replacement. Patients self-serve.
Investment.
- App Store install, live today
- Full content library
- Success criteria agreed upfront · day-45 checkpoint
- Stop anytime, zero clawback
- Branded clinic profile
- 44 guided ketamine integration journeys
- Clinician dashboard with de-identified engagement view
- PHQ-8 and GAD-7 check-ins built in
- Everything in Solo + 5 prescriber seats + unlimited staff/admin seats
- Adverse event flagging + integration-coach handoff workflow
- Spravato 2-hour monitoring module
- Multi-prescriber outcomes dashboard
- Semi-annual outcomes review
- Everything in Clinic + unlimited seats
- Osmind / DrChrono → We Be Now sync (patient roster, appointments)
- Co-branded app + multi-location dashboards
- BAA + SOC 2 documentation (on the compliance roadmap)
- Dedicated Slack or Teams channel
- Bidirectional EHR integration
- Full white-label (clinic in App Store)
- Custom content production
- BAA, SOC 2, HITRUST roadmap
- Dedicated Customer Success Manager
“One retained Spravato patient pays for an entire year of Clinic tier. The math is one-sided.”
Annual billing: 2 months free on every tier · HIPAA compliance in progress, expected next quarter · Patients who self-discover us can subscribe direct on the App Store ($12.99/mo, $79.99/yr). The clinic license unlocks the branded experience, clinician dashboard, and outcomes reporting they can’t get on the consumer app.
Your next step.
Start your 90-day founding pilot today. Setup takes minutes, and your onboarding begins the moment you sign up.
Start our founding pilot →Prefer to talk it through first? hello@katiedickieson.com
Katie Dickieson · Biomedical Engineer (M.Eng, Cornell) · Two-year Spravato + IV ketamine patient
We Be Now™ · 2024-2026 Katie Dickieson · All rights reserved.